Pluristem Therapeutics to Present at Leading Investor Conferences
HAIFA, Israel, Mar 7, 2011 (GlobeNewswire via COMTEX) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (DAX:PJT) (TASE:PLTR) announced today that over the next month, company executives will present at three leading financial events. The presentations follow the recent announcement of positive pre-clinical data from a muscle injury study, successful raise of gross proceeds of more than $40 million in a public offering on Nasdaq, as well as the news announced in January regarding the completion of a parallel scientific advisory process with the EMA and FDA regarding the company's planned clinical development program for PLX-PAD. As previously announced, Pluristem plans to conduct two clinical studies of PLX-PAD and to file the necessary regulatory documentation requesting the joint approval of the FDA-EMA for a Phase II/III study of PLX-PAD for critical limb ischemia (CLI) and a joint approval of the FDA and the Paul Ehrlich Institute (PEI) in Germany to conduct a Phase II study for Intermittent Caludication (IC).
"Since our announcement back in January regarding the completion of the parallel scientific advisory process with the EMA and FDA and the completion of the recent fundraising, we have seen a rapid increase in interest in our Company from the financial, investment and scientific communities," said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. "These presentations will enable us to discuss the competitive advantages of our platform, as well our planned product portfolio, with a number of strategic target audiences."
Over the next month, Pluristem will be presenting at the following conferences:
-- Cowen Annual Health Care Conference, March 7 -- 9, Boston, MA
-- Roth Capital OC Growth Stock Conference, March 13 -- 16, Dana Pt., CA
-- Needham Healthcare Conference, April 5 -- 6, NYC |
